Comment from Certara

Summary: Certara, a pharmaceutical services company, supports the proposed guidance but requests specific clarifications and additions to make it more actionable for sponsors. They advocate for defining tiered evidentiary frameworks, clarifying statistical approaches for small populations, and explicitly recognizing various modeling techniques (like PBPK and QSP) as valid mechanistic data.